Oliver Luxxe Assets’s Pfizer PFE Stock Holding History

Oliver Luxxe Assets’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$452K	Hold	18,762	–	–	0.07%	166
2026 Q1	$527K	Sell	18,762 -2	-0%	-$53	0.08%	159
2025 Q4	$467K	Sell	18,764 -960	-5%	-$24.2K	0.07%	159
2025 Q3	$503K	Buy	19,724 +913	+5%	+$22.5K	0.08%	155
2025 Q2	$456K	Hold	18,811	–	–	0.08%	153
2025 Q1	$477K	Buy	18,811 +401	+2%	+$10.5K	0.09%	156
2024 Q4	$533K	Hold	18,410	–	–	0.1%	152
2024 Q3	$533K	Sell	18,410 -216	-1%	-$6.3K	0.1%	153
2024 Q2	$521K	Buy	18,626 +63	+0.3%	+$1.73K	0.11%	148
2024 Q1	$515K	Hold	18,563	–	–	0.11%	146
2023 Q4	$534K	Hold	18,563	–	–	0.13%	141
2023 Q3	$616K	Sell	18,563 -350	-2%	-$12.4K	0.16%	123
2023 Q2	$694K	Sell	18,913 -940	-5%	-$36.6K	0.17%	120
2023 Q1	$810K	Sell	19,853 -69,089	-78%	-$2.98M	0.21%	102
2022 Q4	$4.56M	Buy	88,942 +53	+0.1%	+$2.54K	1.27%	21
2022 Q3	$3.89M	Buy	88,889 +1,031	+1%	+$50.1K	1.22%	25
2022 Q2	$4.61M	Buy	87,858 +98	+0.1%	+$4.99K	1.36%	18
2022 Q1	$4.54M	Sell	87,760 -210	-0.2%	-$10.9K	1.15%	23
2021 Q4	$5.2M	Sell	87,970 -1,706	-2%	-$84.5K	1.32%	16
2021 Q3	$3.86M	Buy	89,676 +3,321	+4%	+$147K	1.06%	26
2021 Q2	$3.38M	Sell	86,355 -863	-1%	-$33.6K	0.93%	33
2021 Q1	$3.16M	Buy	87,218 +4,382	+5%	+$156K	0.95%	36
2020 Q4	$3.13M	Sell	82,836 -15,896	-16%	-$583K	0.98%	34
2020 Q3	$3.44M	Buy	98,732 +2,926	+3%	+$103K	1.28%	20
2020 Q2	$2.97M	Sell	95,806 -1,259	-1%	-$42.8K	1.56%	21
2020 Q1	$3.19M	Sell	97,065 -19,436	-17%	-$662K	2%	10
2019 Q4	$4.33M	Buy	116,501 +507	+0.4%	+$18.1K	2.26%	5
2019 Q3	$3.9M	Buy	115,994 +8,166	+8%	+$297K	2.27%	5
2019 Q2	$4.43M	Buy	107,828 +1,260	+1%	+$50K	2.46%	3
2019 Q1	$4.29M	Sell	106,568 -3,493	-3%	-$140K	2.49%	3
2018 Q4	$4.56M	Sell	110,061 -7,507	-6%	-$312K	3.07%	1
2018 Q3	$5.01M	Sell	117,568 -5,715	-5%	-$220K	2.84%	2
2018 Q2	$4.15M	Hold	123,283	–	–	2.64%	7
2018 Q1	$4.15M	Sell	123,283 -6,267	-5%	-$215K	2.56%	7
2017 Q4	$4.45M	Sell	129,550 -1,496	-1%	-$51K	2.7%	9
2017 Q3	$4.44M	Sell	131,046 -342	-0.3%	-$11K	2.79%	8
2017 Q2	$4.19M	Buy	131,388 +13,175	+11%	+$415K	2.72%	8
2017 Q1	$3.84M	Buy	118,213 +5,166	+5%	+$163K	2.56%	8
2016 Q4	$3.48M	Buy	113,047 +3,828	+4%	+$117K	2.41%	10
2016 Q3	$3.51M	Buy	109,219 +7,390	+7%	+$247K	2.75%	8
2016 Q2	$3.4M	Sell	101,829 -3,892	-4%	-$124K	2.89%	6
2016 Q1	$2.97M	Buy	105,721 +85,735	+429%	+$2.45M	3.05%	6
2015 Q4	$572K	Buy	+19,986	New	+$629K	0.51%	56

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Oliver Luxxe Assets's PFE Position: Q2 2026 in Review

Oliver Luxxe Assets held its Pfizer (PFE) position steady in Q2 2026 at 18,762 shares worth $452K. The position accounts for 0.07% of the portfolio, ranked #166.

Oliver Luxxe Assets first reported a position in PFE in Q4 2015 and has held it in 43 quarters since. The position peaked at $5.2M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Oliver Luxxe Assets held 18,762 shares of Pfizer worth $452K as of Q2 2026.
Oliver Luxxe Assets left its Pfizer share count unchanged in Q2 2026.
Pfizer made up 0.07% of Oliver Luxxe Assets's portfolio in Q2 2026, its #166 holding.
Oliver Luxxe Assets first reported a position in Pfizer in Q4 2015 and has held it in 43 quarters since.
Oliver Luxxe Assets's Pfizer position peaked at $5.2M in Q4 2021.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Oliver Luxxe Assets's 13F filing for Q2 2026, filed 9 Jul 2026.